Share Price and Basic Stock Data
Last Updated: December 5, 2025, 5:04 am
| PEG Ratio | 1.87 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Blue Jet Healthcare Ltd operates in the pharmaceuticals sector, with a current market capitalization of ₹9,875 Cr. The company reported sales of ₹721 Cr for the fiscal year ending March 2023, reflecting growth from ₹683 Cr in March 2022. However, sales decreased slightly to ₹712 Cr in March 2024 before rebounding significantly to ₹1,030 Cr in March 2025, underscoring a robust recovery trajectory. The trailing twelve months (TTM) sales stood at ₹1,222 Cr, indicating a strong upward trend. Quarterly sales figures reveal fluctuations, with the highest quarterly revenue of ₹340 Cr recorded in March 2025, while June 2022 sales were at ₹145 Cr. Such revenue growth suggests effective market penetration and product demand, particularly in the latter part of the reported period. The trend indicates a positive outlook as the company capitalizes on its operational capabilities and market opportunities in the pharmaceuticals domain.
Profitability and Efficiency Metrics
Blue Jet Healthcare reported a net profit of ₹160 Cr for the fiscal year ending March 2023, which increased significantly to ₹305 Cr in March 2025, resulting in a net profit margin of 29.6% for that year. The operating profit margin (OPM) also demonstrated resilience, standing at 30% in March 2023 and increasing to 37% in March 2025. The interest coverage ratio (ICR) was exceptionally high at 40.49x, indicating strong earnings relative to interest expenses, reflecting financial stability. The company has maintained robust profitability metrics, with a return on equity (ROE) at 30.2% and return on capital employed (ROCE) at 39.8%. However, the cash conversion cycle (CCC) has lengthened to 262 days, suggesting potential inefficiencies in managing working capital. Overall, Blue Jet Healthcare’s profitability metrics position it favorably within the competitive pharmaceuticals sector, but the prolonged CCC could be an area for improvement.
Balance Sheet Strength and Financial Ratios
Blue Jet Healthcare’s financial position is characterized by low borrowings, amounting to just ₹21 Cr, against reserves of ₹1,221 Cr as of September 2025. This solid reserve base provides a cushion for future investments and operational needs. The company’s total liabilities stood at ₹1,527 Cr, with total assets at ₹1,527 Cr, indicating a balanced sheet structure. The company has reported a book value of ₹35 per share, while the price-to-earnings (P/E) ratio is at 28.0, reflecting investor confidence in the company’s growth potential. The asset turnover ratio indicates efficient utilization of assets, while the current ratio of 2.43 suggests that Blue Jet can easily cover its short-term obligations. However, the absence of a price-to-book value (P/BV) metric limits some insights into the valuation relative to its equity. Overall, the balance sheet reflects a healthy financial structure, promoting investor confidence.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Blue Jet Healthcare reveals significant promoter ownership at 79.81%, indicating strong management control and commitment to the company. Foreign institutional investors (FIIs) hold a modest 1.83%, while domestic institutional investors (DIIs) account for 3.63%. The public shareholding stands at 14.74%, which has increased from 7.37% in December 2023, suggesting growing investor interest. The total number of shareholders rose to 80,117 by September 2025, up from 55,589 in December 2023, reflecting increased retail participation. The consistent promoter holding around 86% during the earlier quarters indicates stability, while the gradual increase in public shareholding may enhance liquidity. However, the low FII and DII participation could be a concern for broader institutional confidence. Overall, the shareholding dynamics reflect a mix of stability and potential for increased retail engagement.
Outlook, Risks, and Final Insight
The outlook for Blue Jet Healthcare appears optimistic, driven by a strong recovery in sales and profitability metrics. The significant increase in net profit to ₹305 Cr in March 2025 demonstrates effective operational strategies. However, risks include a prolonged cash conversion cycle of 262 days, which may affect liquidity and operational efficiency. Additionally, reliance on a limited number of institutional investors poses a risk for market volatility. The potential for growth remains strong, particularly if the company can streamline its working capital management. Should Blue Jet Healthcare continue its trajectory of revenue growth and profitability while addressing operational inefficiencies, it is well-positioned to enhance shareholder value. Conversely, failure to manage cash flow effectively could hinder its financial strength and market position.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Blue Jet Healthcare Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 148 Cr. | 118 | 247/84.3 | 32.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,222 Cr. | 387 | 479/192 | 87.4 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.4 Cr. | 47.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 43.1 Cr. | 29.4 | 30.5/17.0 | 103 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,616.17 Cr | 1,175.51 | 52.55 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 145 | 190 | 169 | 217 | 180 | 181 | 167 | 184 | 163 | 208 | 318 | 340 | 355 |
| Expenses | 106 | 132 | 117 | 147 | 121 | 119 | 112 | 131 | 119 | 139 | 194 | 200 | 234 |
| Operating Profit | 38 | 59 | 52 | 70 | 59 | 63 | 55 | 53 | 44 | 69 | 124 | 140 | 121 |
| OPM % | 27% | 31% | 31% | 32% | 33% | 35% | 33% | 29% | 27% | 33% | 39% | 41% | 34% |
| Other Income | 4 | 7 | 6 | 6 | 5 | 8 | -3 | 9 | 9 | 12 | 13 | 12 | 8 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 6 | 6 | 7 | 6 | 6 | 6 | 8 | 8 | 3 | 5 | 5 | 5 | 6 |
| Profit before tax | 36 | 59 | 51 | 70 | 58 | 64 | 44 | 54 | 49 | 77 | 132 | 147 | 123 |
| Tax % | 24% | 26% | 27% | 27% | 24% | 26% | 27% | 27% | 24% | 24% | 25% | 25% | 26% |
| Net Profit | 28 | 44 | 38 | 51 | 44 | 48 | 32 | 40 | 38 | 58 | 99 | 110 | 91 |
| EPS in Rs | 1.61 | 2.53 | 2.16 | 2.92 | 2.54 | 2.76 | 1.85 | 2.29 | 2.18 | 3.36 | 5.71 | 6.35 | 5.26 |
Last Updated: August 1, 2025, 6:00 am
Below is a detailed analysis of the quarterly data for Blue Jet Healthcare Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 355.00 Cr.. The value appears strong and on an upward trend. It has increased from 340.00 Cr. (Mar 2025) to 355.00 Cr., marking an increase of 15.00 Cr..
- For Expenses, as of Jun 2025, the value is 234.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 200.00 Cr. (Mar 2025) to 234.00 Cr., marking an increase of 34.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 121.00 Cr.. The value appears to be declining and may need further review. It has decreased from 140.00 Cr. (Mar 2025) to 121.00 Cr., marking a decrease of 19.00 Cr..
- For OPM %, as of Jun 2025, the value is 34.00%. The value appears to be declining and may need further review. It has decreased from 41.00% (Mar 2025) to 34.00%, marking a decrease of 7.00%.
- For Other Income, as of Jun 2025, the value is 8.00 Cr.. The value appears to be declining and may need further review. It has decreased from 12.00 Cr. (Mar 2025) to 8.00 Cr., marking a decrease of 4.00 Cr..
- For Interest, as of Jun 2025, the value is 1.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.00 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Mar 2025) to 6.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 123.00 Cr.. The value appears to be declining and may need further review. It has decreased from 147.00 Cr. (Mar 2025) to 123.00 Cr., marking a decrease of 24.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Mar 2025) to 26.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 91.00 Cr.. The value appears to be declining and may need further review. It has decreased from 110.00 Cr. (Mar 2025) to 91.00 Cr., marking a decrease of 19.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 5.26. The value appears to be declining and may need further review. It has decreased from 6.35 (Mar 2025) to 5.26, marking a decrease of 1.09.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:44 am
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 538 | 499 | 683 | 721 | 712 | 1,030 | 1,222 |
| Expenses | 325 | 292 | 434 | 502 | 481 | 652 | 767 |
| Operating Profit | 214 | 207 | 249 | 219 | 231 | 378 | 454 |
| OPM % | 40% | 41% | 36% | 30% | 32% | 37% | 37% |
| Other Income | 6 | 9 | 19 | 24 | 18 | 46 | 46 |
| Interest | 7 | 5 | 3 | 1 | 0 | 0 | 1 |
| Depreciation | 18 | 20 | 22 | 25 | 28 | 18 | 20 |
| Profit before tax | 194 | 190 | 243 | 217 | 220 | 406 | 479 |
| Tax % | 25% | 26% | 25% | 26% | 26% | 25% | |
| Net Profit | 145 | 142 | 182 | 160 | 164 | 305 | 359 |
| EPS in Rs | 24,118.33 | 1,428.57 | 10.47 | 9.23 | 9.44 | 17.59 | 20.68 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 11% | 7% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -2.07% | 28.17% | -12.09% | 2.50% | 85.98% |
| Change in YoY Net Profit Growth (%) | 0.00% | 30.24% | -40.26% | 14.59% | 83.48% |
Blue Jet Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 15% |
| TTM: | 76% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 19% |
| TTM: | 118% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 48% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 31% |
| 3 Years: | 27% |
| Last Year: | 31% |
Last Updated: September 5, 2025, 2:45 pm
Balance Sheet
Last Updated: December 4, 2025, 2:33 am
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.60 | 10 | 35 | 35 | 35 | 35 | 35 |
| Reserves | 198 | 330 | 487 | 647 | 811 | 1,098 | 1,221 |
| Borrowings | 74 | 52 | 19 | 5 | 3 | 21 | 21 |
| Other Liabilities | 92 | 142 | 173 | 176 | 211 | 263 | 251 |
| Total Liabilities | 364 | 534 | 713 | 862 | 1,059 | 1,418 | 1,527 |
| Fixed Assets | 107 | 139 | 156 | 151 | 172 | 300 | 303 |
| CWIP | 2 | 3 | 3 | 30 | 147 | 89 | 159 |
| Investments | 26 | 37 | 94 | 189 | 250 | 187 | 210 |
| Other Assets | 229 | 355 | 460 | 491 | 489 | 841 | 855 |
| Total Assets | 364 | 534 | 713 | 862 | 1,059 | 1,418 | 1,527 |
Below is a detailed analysis of the balance sheet data for Blue Jet Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 35.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 35.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,221.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,098.00 Cr. (Mar 2025) to 1,221.00 Cr., marking an increase of 123.00 Cr..
- For Borrowings, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 251.00 Cr.. The value appears to be improving (decreasing). It has decreased from 263.00 Cr. (Mar 2025) to 251.00 Cr., marking a decrease of 12.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,527.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,418.00 Cr. (Mar 2025) to 1,527.00 Cr., marking an increase of 109.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 303.00 Cr.. The value appears strong and on an upward trend. It has increased from 300.00 Cr. (Mar 2025) to 303.00 Cr., marking an increase of 3.00 Cr..
- For CWIP, as of Sep 2025, the value is 159.00 Cr.. The value appears strong and on an upward trend. It has increased from 89.00 Cr. (Mar 2025) to 159.00 Cr., marking an increase of 70.00 Cr..
- For Investments, as of Sep 2025, the value is 210.00 Cr.. The value appears strong and on an upward trend. It has increased from 187.00 Cr. (Mar 2025) to 210.00 Cr., marking an increase of 23.00 Cr..
- For Other Assets, as of Sep 2025, the value is 855.00 Cr.. The value appears strong and on an upward trend. It has increased from 841.00 Cr. (Mar 2025) to 855.00 Cr., marking an increase of 14.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,527.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,418.00 Cr. (Mar 2025) to 1,527.00 Cr., marking an increase of 109.00 Cr..
Notably, the Reserves (1,221.00 Cr.) exceed the Borrowings (21.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Free Cash Flow | 140.00 | 155.00 | 230.00 | 214.00 | 228.00 | 357.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 80 | 105 | 121 | 121 | 91 | 124 |
| Inventory Days | 120 | 201 | 133 | 137 | 151 | 209 |
| Days Payable | 90 | 101 | 72 | 58 | 35 | 70 |
| Cash Conversion Cycle | 110 | 204 | 183 | 199 | 206 | 262 |
| Working Capital Days | 55 | 105 | 103 | 120 | 92 | 157 |
| ROCE % | 58% | 53% | 35% | 30% | 40% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 1,121,784 | 1.14 | 73.63 | 1,080,413 | 2025-11-03 11:50:43 | 3.83% |
| UTI Small Cap Fund | 506,107 | 0.68 | 33.22 | N/A | N/A | N/A |
| PGIM India Flexi Cap Fund | 421,553 | 0.43 | 27.67 | N/A | N/A | N/A |
| JM Flexicap Fund | 419,500 | 0.45 | 27.54 | N/A | N/A | N/A |
| JM Midcap Fund | 139,800 | 0.62 | 9.18 | N/A | N/A | N/A |
| PGIM India Small Cap Fund | 118,519 | 0.48 | 7.78 | N/A | N/A | N/A |
| JM ELSS Tax Saver Fund | 53,400 | 1.56 | 3.51 | N/A | N/A | N/A |
| JM Aggressive Hybrid Fund | 47,900 | 0.39 | 3.14 | N/A | N/A | N/A |
| JM Large Cap Fund | 41,900 | 0.56 | 2.75 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 21 | Mar 20 |
|---|---|---|
| FaceValue | 100.00 | 100.00 |
| Basic EPS (Rs.) | 1396.27 | 1462.59 |
| Diluted EPS (Rs.) | 1396.27 | 1462.59 |
| Cash EPS (Rs.) | 1568.30 | 27166.33 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 3428.34 | 32238.33 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 3428.34 | 32238.33 |
| Revenue From Operations / Share (Rs.) | 5033.61 | 89699.16 |
| PBDIT / Share (Rs.) | 2168.43 | 36589.16 |
| PBIT / Share (Rs.) | 1970.05 | 33582.66 |
| PBT / Share (Rs.) | 1862.96 | 32354.50 |
| Net Profit / Share (Rs.) | 1369.92 | 24159.83 |
| NP After MI And SOA / Share (Rs.) | 1396.43 | 24141.33 |
| PBDIT Margin (%) | 43.07 | 40.79 |
| PBIT Margin (%) | 39.13 | 37.43 |
| PBT Margin (%) | 37.01 | 36.07 |
| Net Profit Margin (%) | 27.21 | 26.93 |
| NP After MI And SOA Margin (%) | 27.74 | 26.91 |
| Return on Networth / Equity (%) | 40.73 | 75.40 |
| Return on Capital Employeed (%) | 52.32 | 83.21 |
| Return On Assets (%) | 25.94 | 38.58 |
| Long Term Debt / Equity (X) | 0.08 | 0.19 |
| Total Debt / Equity (X) | 0.10 | 0.30 |
| Asset Turnover Ratio (%) | 1.10 | 0.00 |
| Current Ratio (X) | 2.43 | 1.89 |
| Quick Ratio (X) | 1.69 | 1.37 |
| Inventory Turnover Ratio (X) | 2.30 | 0.00 |
| Interest Coverage Ratio (X) | 40.49 | 29.79 |
| Interest Coverage Ratio (Post Tax) (X) | 27.58 | 20.67 |
After reviewing the key financial ratios for Blue Jet Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 21, the value is 100.00. This value exceeds the healthy maximum of 10. There is no change compared to the previous period (Mar 20) which recorded 100.00.
- For Basic EPS (Rs.), as of Mar 21, the value is 1,396.27. This value is within the healthy range. It has decreased from 1,462.59 (Mar 20) to 1,396.27, marking a decrease of 66.32.
- For Diluted EPS (Rs.), as of Mar 21, the value is 1,396.27. This value is within the healthy range. It has decreased from 1,462.59 (Mar 20) to 1,396.27, marking a decrease of 66.32.
- For Cash EPS (Rs.), as of Mar 21, the value is 1,568.30. This value is within the healthy range. It has decreased from 27,166.33 (Mar 20) to 1,568.30, marking a decrease of 25,598.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 21, the value is 3,428.34. It has decreased from 32,238.33 (Mar 20) to 3,428.34, marking a decrease of 28,809.99.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 21, the value is 3,428.34. It has decreased from 32,238.33 (Mar 20) to 3,428.34, marking a decrease of 28,809.99.
- For Revenue From Operations / Share (Rs.), as of Mar 21, the value is 5,033.61. It has decreased from 89,699.16 (Mar 20) to 5,033.61, marking a decrease of 84,665.55.
- For PBDIT / Share (Rs.), as of Mar 21, the value is 2,168.43. This value is within the healthy range. It has decreased from 36,589.16 (Mar 20) to 2,168.43, marking a decrease of 34,420.73.
- For PBIT / Share (Rs.), as of Mar 21, the value is 1,970.05. This value is within the healthy range. It has decreased from 33,582.66 (Mar 20) to 1,970.05, marking a decrease of 31,612.61.
- For PBT / Share (Rs.), as of Mar 21, the value is 1,862.96. This value is within the healthy range. It has decreased from 32,354.50 (Mar 20) to 1,862.96, marking a decrease of 30,491.54.
- For Net Profit / Share (Rs.), as of Mar 21, the value is 1,369.92. This value is within the healthy range. It has decreased from 24,159.83 (Mar 20) to 1,369.92, marking a decrease of 22,789.91.
- For NP After MI And SOA / Share (Rs.), as of Mar 21, the value is 1,396.43. This value is within the healthy range. It has decreased from 24,141.33 (Mar 20) to 1,396.43, marking a decrease of 22,744.90.
- For PBDIT Margin (%), as of Mar 21, the value is 43.07. This value is within the healthy range. It has increased from 40.79 (Mar 20) to 43.07, marking an increase of 2.28.
- For PBIT Margin (%), as of Mar 21, the value is 39.13. This value exceeds the healthy maximum of 20. It has increased from 37.43 (Mar 20) to 39.13, marking an increase of 1.70.
- For PBT Margin (%), as of Mar 21, the value is 37.01. This value is within the healthy range. It has increased from 36.07 (Mar 20) to 37.01, marking an increase of 0.94.
- For Net Profit Margin (%), as of Mar 21, the value is 27.21. This value exceeds the healthy maximum of 10. It has increased from 26.93 (Mar 20) to 27.21, marking an increase of 0.28.
- For NP After MI And SOA Margin (%), as of Mar 21, the value is 27.74. This value exceeds the healthy maximum of 20. It has increased from 26.91 (Mar 20) to 27.74, marking an increase of 0.83.
- For Return on Networth / Equity (%), as of Mar 21, the value is 40.73. This value is within the healthy range. It has decreased from 75.40 (Mar 20) to 40.73, marking a decrease of 34.67.
- For Return on Capital Employeed (%), as of Mar 21, the value is 52.32. This value is within the healthy range. It has decreased from 83.21 (Mar 20) to 52.32, marking a decrease of 30.89.
- For Return On Assets (%), as of Mar 21, the value is 25.94. This value is within the healthy range. It has decreased from 38.58 (Mar 20) to 25.94, marking a decrease of 12.64.
- For Long Term Debt / Equity (X), as of Mar 21, the value is 0.08. This value is below the healthy minimum of 0.2. It has decreased from 0.19 (Mar 20) to 0.08, marking a decrease of 0.11.
- For Total Debt / Equity (X), as of Mar 21, the value is 0.10. This value is within the healthy range. It has decreased from 0.30 (Mar 20) to 0.10, marking a decrease of 0.20.
- For Asset Turnover Ratio (%), as of Mar 21, the value is 1.10. It has increased from 0.00 (Mar 20) to 1.10, marking an increase of 1.10.
- For Current Ratio (X), as of Mar 21, the value is 2.43. This value is within the healthy range. It has increased from 1.89 (Mar 20) to 2.43, marking an increase of 0.54.
- For Quick Ratio (X), as of Mar 21, the value is 1.69. This value is within the healthy range. It has increased from 1.37 (Mar 20) to 1.69, marking an increase of 0.32.
- For Inventory Turnover Ratio (X), as of Mar 21, the value is 2.30. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 20) to 2.30, marking an increase of 2.30.
- For Interest Coverage Ratio (X), as of Mar 21, the value is 40.49. This value is within the healthy range. It has increased from 29.79 (Mar 20) to 40.49, marking an increase of 10.70.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 21, the value is 27.58. This value is within the healthy range. It has increased from 20.67 (Mar 20) to 27.58, marking an increase of 6.91.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Blue Jet Healthcare Ltd:
- Net Profit Margin: 27.21%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 52.32% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 40.73% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 27.58
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.69
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 27.3 (Industry average Stock P/E: 52.55)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.1
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 27.21%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 701, 702, 7th Floor, Navi Mumbai Maharashtra 400705 | companysecretary@bluejethealthcare.com http://www.bluejethealthcare.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Akshay Bansarilal Arora | Executive Chairman |
| Mr. Shiven Akshay Arora | Managing Director |
| Mr. Naresh Suryakant Shah | Executive Director |
| Ms. Divya Sameer Momaya | Independent Director |
| Mr. Girish Paman Vanvari | Independent Director |
| Ms. Preeti Gautam Mehta | Independent Director |
FAQ
What is the intrinsic value of Blue Jet Healthcare Ltd?
Blue Jet Healthcare Ltd's intrinsic value (as of 04 December 2025) is 478.58 which is 13.77% lower the current market price of 555.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 9,624 Cr. market cap, FY2025-2026 high/low of 1,028/492, reserves of ₹1,221 Cr, and liabilities of 1,527 Cr.
What is the Market Cap of Blue Jet Healthcare Ltd?
The Market Cap of Blue Jet Healthcare Ltd is 9,624 Cr..
What is the current Stock Price of Blue Jet Healthcare Ltd as on 04 December 2025?
The current stock price of Blue Jet Healthcare Ltd as on 04 December 2025 is 555.
What is the High / Low of Blue Jet Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Blue Jet Healthcare Ltd stocks is 1,028/492.
What is the Stock P/E of Blue Jet Healthcare Ltd?
The Stock P/E of Blue Jet Healthcare Ltd is 27.3.
What is the Book Value of Blue Jet Healthcare Ltd?
The Book Value of Blue Jet Healthcare Ltd is 72.4.
What is the Dividend Yield of Blue Jet Healthcare Ltd?
The Dividend Yield of Blue Jet Healthcare Ltd is 0.22 %.
What is the ROCE of Blue Jet Healthcare Ltd?
The ROCE of Blue Jet Healthcare Ltd is 39.8 %.
What is the ROE of Blue Jet Healthcare Ltd?
The ROE of Blue Jet Healthcare Ltd is 30.2 %.
What is the Face Value of Blue Jet Healthcare Ltd?
The Face Value of Blue Jet Healthcare Ltd is 2.00.